EMBC | Embecta Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	19.30 - 20.44
52 Week Range	9.93 - 21.48
Beta	0.65
Implied Volatility	59.32%
IV Rank	2.86%
Day's Volume	1,042,623
Average Volume	367,822
Shares Outstanding	58,130,560
Market Cap	1,175,981,229
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2022-03-22

Valuation
Profitability
Growth
Health
P/E Ratio	15.10
Forward P/E Ratio	5.95
EPS	1.34
1YR Price Target	29.00
Dividend Yield	3.08%
Dividend Per Share	0.62
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2,200
Country	USA
Website	EMBC

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

EMBC's peers: ALC, BAX, ISRG, RMD, WST, COO, ICUI, MMSI, ANGO, ATR, TFX, HAE, NVST, AKYA, ATRC, ATRI

*Chart delayed

Analyzing fundamentals for EMBC we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see EMBC Fundamentals page.

Watching at EMBC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on EMBC Technicals page.